From EU regulatory probes to resurgent outbreaks, the vaccine landscape is shaped by corporate rivalry, political pressure, and shifting public health priorities.

The European Commission has launched an antitrust investigation into Sanofi, a French pharmaceutical giant, over allegations that it disparaged rival flu vaccines to dominate the market. The...

Internal emails from the U.S. Department of Health and Human Services (HHS), released by Senator Bernie Sanders, reveal that Robert F. Kennedy Jr. (RFK Jr.) pressured the CDC to alter its va...

Measles outbreaks in Pennsylvania and Romania signal a troubling decline in vaccination coverage. Pennsylvania reported cases in two additional counties, prompting health officials to recomm...

The vaccine landscape in 2026 is defined by a paradox: unprecedented scientific advancements coexist with deepening public distrust and regulatory challenges. The EU's antitrust probe into Sanofi signals a crackdown on corporate practices that undermine fair competition, while political pressures on agencies like the CDC highlight the fragility of public health messaging. Resurgent measles outbreaks and military vaccine mandates underscore the urgent need for equitable immunization strategies and transparent communication. Looking ahead, the future of vaccines will depend on rebuilding trust, addressing misinformation, and ensuring that corporate and political interests do not overshadow public health priorities. The stakes are high: the success or failure of these efforts will determine whether immunization remains a cornerstone of global health—or a casualty of polarization and profit-driven agendas.